Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease characterized by irreversible scarring of the lungs. The cause of IPF is unknown, but it is thought to involve a combination of genetic and environmental factors. There is no cure for IPF, and trea...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.1079 |
| _version_ | 1797404087959945216 |
|---|---|
| author | Dalia D. Hadi Mohammed Dheyaa Marsool Marsool Ali Dheyaa Marsool Marsool Neel Vora Sajjad G. Al‐Badri Nabeel H. K. Al‐Fatlawi Ameer F. Abbas Al Wssawi Abdullah M. T. Al‐Ibraheem Khadija A. Hamza Priyadarshi Prajjwal Mohammed A. Mateen Omniat Amir |
| author_facet | Dalia D. Hadi Mohammed Dheyaa Marsool Marsool Ali Dheyaa Marsool Marsool Neel Vora Sajjad G. Al‐Badri Nabeel H. K. Al‐Fatlawi Ameer F. Abbas Al Wssawi Abdullah M. T. Al‐Ibraheem Khadija A. Hamza Priyadarshi Prajjwal Mohammed A. Mateen Omniat Amir |
| author_sort | Dalia D. Hadi |
| collection | DOAJ |
| description | Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease characterized by irreversible scarring of the lungs. The cause of IPF is unknown, but it is thought to involve a combination of genetic and environmental factors. There is no cure for IPF, and treatment is focused on slowing disease progression and relieving symptoms. Aims We aimed in this review to investigate and provide the latest insights into IPF management modalities, including the potential of Saracatinibas a substitute for current IPF drugs. We also investigated the therapeutic potential of Sotatercept in addressing pulmonary hypertension associated with IPF. Materials and Methods We conducted a comprehensive literature review of relevant studies on IPF management. We searched electronic databases, including PubMed, Scopus, Embase, and Web of science. Results The two Food and Drug Administration‐approved drugs for IPF, Pirfenidone, and Nintedanib, have been pivotal in slowing disease progression, yet experimental evidence suggests that Saracatinib surpasses their efficacy. Preclinical trials investigating the potential of Saracatinib, a tyrosine kinase inhibitor, have shown to be more effective than current IPF drugs in slowing disease progression in preclinical studies. Also, Sotatercept,a fusion protein, has been shown to reduce pulmonary vascular resistance and improve exercise tolerance in patients with PH associated with IPF in clinical trials. Conclusions The advancements discussed in this review hold the promise of improving the quality of life for IPF patients and enhancing our understanding of this condition. There remains a need for further research to confirm the efficacy and safety of new IPF treatments and to develop more effective strategies for managing exacerbations. |
| first_indexed | 2024-03-09T02:49:50Z |
| format | Article |
| id | doaj.art-00209de17b56481891f71d3b0a5b5385 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-03-09T02:49:50Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-00209de17b56481891f71d3b0a5b53852023-12-05T11:18:02ZengWileyImmunity, Inflammation and Disease2050-45272023-11-011111n/an/a10.1002/iid3.1079Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertensionDalia D. Hadi0Mohammed Dheyaa Marsool Marsool1Ali Dheyaa Marsool Marsool2Neel Vora3Sajjad G. Al‐Badri4Nabeel H. K. Al‐Fatlawi5Ameer F. Abbas Al Wssawi6Abdullah M. T. Al‐Ibraheem7Khadija A. Hamza8Priyadarshi Prajjwal9Mohammed A. Mateen10Omniat Amir11Department of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad IraqDepartment of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad IraqDepartment of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad IraqDepartment Internal Medicine B.J. Medical College Ahmedabad IndiaDepartment of Internal Medicine University of Baghdad, College of Medicine Baghdad IraqDepartment of Internal Medicine University of Baghdad, College of Medicine Baghdad IraqDepartment of Internal Medicine University of Al‐Qadisiyah College of Medicine Diwaniya IraqDepartment of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad IraqDepartment of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad IraqDepartment of Internal Medicine Bharati Vidyapeeth University Medical College Pune IndiaDepartment of Internal Medicine Shadan Institute of Medical Sciences Teaching Hospital and Research Center Hyderabad IndiaDepartment of Internal Medicine Al Manhal Academy Khartoum SudanAbstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease characterized by irreversible scarring of the lungs. The cause of IPF is unknown, but it is thought to involve a combination of genetic and environmental factors. There is no cure for IPF, and treatment is focused on slowing disease progression and relieving symptoms. Aims We aimed in this review to investigate and provide the latest insights into IPF management modalities, including the potential of Saracatinibas a substitute for current IPF drugs. We also investigated the therapeutic potential of Sotatercept in addressing pulmonary hypertension associated with IPF. Materials and Methods We conducted a comprehensive literature review of relevant studies on IPF management. We searched electronic databases, including PubMed, Scopus, Embase, and Web of science. Results The two Food and Drug Administration‐approved drugs for IPF, Pirfenidone, and Nintedanib, have been pivotal in slowing disease progression, yet experimental evidence suggests that Saracatinib surpasses their efficacy. Preclinical trials investigating the potential of Saracatinib, a tyrosine kinase inhibitor, have shown to be more effective than current IPF drugs in slowing disease progression in preclinical studies. Also, Sotatercept,a fusion protein, has been shown to reduce pulmonary vascular resistance and improve exercise tolerance in patients with PH associated with IPF in clinical trials. Conclusions The advancements discussed in this review hold the promise of improving the quality of life for IPF patients and enhancing our understanding of this condition. There remains a need for further research to confirm the efficacy and safety of new IPF treatments and to develop more effective strategies for managing exacerbations.https://doi.org/10.1002/iid3.1079idiopathic pulmonary fibrosismanagementpulmonary hypertensionSotatercept |
| spellingShingle | Dalia D. Hadi Mohammed Dheyaa Marsool Marsool Ali Dheyaa Marsool Marsool Neel Vora Sajjad G. Al‐Badri Nabeel H. K. Al‐Fatlawi Ameer F. Abbas Al Wssawi Abdullah M. T. Al‐Ibraheem Khadija A. Hamza Priyadarshi Prajjwal Mohammed A. Mateen Omniat Amir Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension Immunity, Inflammation and Disease idiopathic pulmonary fibrosis management pulmonary hypertension Sotatercept |
| title | Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension |
| title_full | Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension |
| title_fullStr | Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension |
| title_full_unstemmed | Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension |
| title_short | Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension |
| title_sort | idiopathic pulmonary fibrosis addressing the current and future therapeutic advances along with the role of sotatercept in the management of pulmonary hypertension |
| topic | idiopathic pulmonary fibrosis management pulmonary hypertension Sotatercept |
| url | https://doi.org/10.1002/iid3.1079 |
| work_keys_str_mv | AT daliadhadi idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT mohammeddheyaamarsoolmarsool idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT alidheyaamarsoolmarsool idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT neelvora idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT sajjadgalbadri idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT nabeelhkalfatlawi idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT ameerfabbasalwssawi idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT abdullahmtalibraheem idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT khadijaahamza idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT priyadarshiprajjwal idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT mohammedamateen idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension AT omniatamir idiopathicpulmonaryfibrosisaddressingthecurrentandfuturetherapeuticadvancesalongwiththeroleofsotaterceptinthemanagementofpulmonaryhypertension |